Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Astra describes prodrugs of thrombin inhibitors

Sep. 26, 1997

rNAPc2 completes phase Ia testing with positive results

Sep. 25, 1997

Lilly presents structurally novel thrombin inhibitors

Sep. 24, 1997

First approvals for Lovenox/Clexane in unstable angina/MI

Sep. 22, 1997

TP-9201 as adjunct to thrombolysis in stroke

Sep. 22, 1997

Lilly describes lead for orally active thrombin inhibitors

Sep. 19, 1997

Bisulfated peptide may be clinically useful in venous thrombotic disorders

Sep. 17, 1997

Long-term effects of abciximab in PTCA

Sep. 16, 1997

Molecumetics and Teijin begin oral thrombin inhibitor collaboration

Sep. 15, 1997

Pharmacological characterization of BIBU-52

Sep. 15, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...
How to Summit up? Dis-Harmoni on ivonescimab NSCLC phase III
BioWorld
Wall Street pundits were divided about the likely fate of ivonescimab, Summit Therapeutics Inc.’s bispecific antibody partnered with Akeso Pharmaceuticals Inc.,...